Skip to main content

Cullinan Therapeutics, Inc.

CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001789972

In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Cullinan Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
1 insider, $922.9K in total
Insiders trading
1
Net value
−$922.9K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Cullinan Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Cullinan Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Michaelson JenniferChief Scientific Officer158,844Sep 10, 202615
Sumer Jacquelyn LChief Legal Officer130,559Jul 2, 20265
Fenton Mary KayChief Financial Officer127,921Jul 2, 20264
Thistle MaryDirector–Jun 18, 20261
Allen Andrew RDirector–Jun 18, 20261
Webster Stephen WDirector–Jun 18, 20261
Rosenberg AnthonyDirector–Jun 18, 20261
Meek David D.Director–Jun 18, 20261
Doyle MittieDirector–Jun 18, 20261
Ahmed NadimPresident and CEO390,803Feb 25, 20264
Jones Jeffrey AlanChief Medical Officer159,968Feb 25, 20264
Savill CorrineChief Business Officer240,990Feb 19, 20261
Nichols Weston10% Owner8,963,500IndirectOct 30, 20253
Lynx1 Capital Management LP10% Owner8,963,500IndirectOct 30, 20253
Martin Anne-MarieDirector–Jun 16, 20250
Ryan David P.Director–Jun 16, 20250
Ebeling ThomasDirector186,653Jun 11, 20240
Trigilio JeffreyChief Financial Officer133,919Feb 23, 20240
Baeuerle PatrickChief Scientific Officer76,000Feb 21, 20230
Biotechnology Value Fund L POther: See Explanation of Responses64,161Jan 19, 20230
BVF Partners L P10% Owner64,161Jan 19, 20230
BVF Inc10% Owner64,161Jan 19, 20230
Biotechnology Value Fund II LPOther: See Explanation of Responses64,161Jan 19, 20230
Lampert Mark N10% Owner64,161Jan 19, 20230
Biotechnology Value Trading Fund OS LPOther: See Explanation of Responses64,161Jan 19, 20230
BVF Partners OS Ltd.Other: See Explanation of Responses64,161Jan 19, 20230
BVF I GP LLCOther: See Explanation of Responses64,161Jan 19, 20230
BVF II GP LLCOther: See Explanation of Responses64,161Jan 19, 20230
BVF GP Holdings LLC10% Owner64,161Jan 19, 20230
Jovan-Embiricos Morana10% Owner1,255,963Aug 4, 20220
F2 Vision SCS10% Owner1,255,963Aug 4, 20220
F2 Bioscience I 2017 Ltd10% Owner537,392Jun 23, 20220
Gadicke AnsbertDirector7,648,268IndirectJun 23, 20220
Keane Raymond TChief Legal Officer24,124Feb 15, 20220
Zawel LeighSee Remarks69,785Feb 15, 20220
MPM BioImpact LLC10% Owner7,648,268Sep 20, 20210
UBS Oncology Impact Fund L.P.10% Owner7,648,268Sep 20, 20210
Oncology Impact Fund (Cayman) Management L.P.10% Owner7,648,268Sep 20, 20210
MPM Oncology Impact Management GP LLC10% Owner7,805,483Aug 25, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 12, 2021 (view filing)Aug 111 dayGadicke AnsbertDirector, 10% OwnerSSale−347$29.05−$10.1K−0.1%280.9K after
Aug 12, 2021 (view filing)Aug 111 dayGadicke AnsbertDirector, 10% OwnerSSale−2.51K$29.05−$72.9K0.0%7.91M after
Aug 12, 2021 (view filing)4:55 PM ETAug 111 dayMPM BioImpact LLC and 3 others10% OwnerSSale−2.51K$29.05−$72.9K0.0%7.91M afterDuplicate filing
Aug 25, 2021 (view filing)Aug 23-252 daysGadicke AnsbertDirector, 10% OwnerSSale−14.6K$29.29−$428.7K−5.2%266.3K after3 lots
Aug 25, 2021 (view filing)Aug 23-252 daysGadicke AnsbertDirector, 10% OwnerSSale−106.0K$29.29−$3.10M−1.3%7.81M after3 lots
Aug 25, 2021 (view filing)7:42 PM ETAug 23-252 daysMPM BioImpact LLC and 3 others10% OwnerSSale−105.9K$29.29−$3.10M−1.3%7.81M after3 lots
Aug 26, 2021 (view filing)Aug 1016 daysLateBaeuerle PatrickSee RemarksSSale−11.0K$27.00−$297.0K−100.0%0 after
Aug 26, 2021 (view filing)Aug 233 daysZawel LeighSee RemarksSSale−28.1K$29.00−$815.4K−23.1%93.5K afterAmended
Aug 26, 2021 (view filing)Aug 188 daysMichaelson JenniferSee RemarksSSale−4.00K$27.66−$110.6K−14.9%22.9K afterAmended2 lots
Aug 26, 2021 (view filing)Aug 9-1017 daysZawel LeighSee RemarksSSale−28.1K$26.77−$752.9K−18.8%121.6K afterAmended5 lots
Aug 31, 2021 (view filing)Aug 27-304 daysGadicke AnsbertDirector, 10% OwnerSSale−6.13K$29.24−$179.3K−2.3%260.2K after2 lots
Aug 31, 2021 (view filing)Aug 27-304 daysGadicke AnsbertDirector, 10% OwnerSSale−44.4K$29.24−$1.30M−0.6%7.76M after2 lots
Aug 31, 2021 (view filing)4:47 PM ETAug 27-304 daysMPM BioImpact LLC and 2 others10% OwnerSSale−44.4K$29.24−$1.30M−0.6%7.76M after2 lotsDuplicate filing
Sep 2, 2021 (view filing)Aug 31-Sep 22 daysGadicke AnsbertDirector, 10% OwnerSSale−3.36K$29.50−$99.1K−1.3%256.8K after4 lots
Sep 2, 2021 (view filing)Aug 31-Sep 22 daysGadicke AnsbertDirector, 10% OwnerSSale−24.3K$29.50−$717.2K−0.3%7.74M after4 lots
Sep 2, 2021 (view filing)5:26 PM ETAug 31-Sep 22 daysMPM BioImpact LLC and 2 others10% OwnerSSale−24.3K$29.50−$717.2K−0.3%7.74M after4 lotsDuplicate filing
Sep 8, 2021 (view filing)Sep 71 dayZawel LeighSee RemarksSSale−28.1K$28.95−$814.0K−30.1%65.4K after
Sep 8, 2021 (view filing)Sep 3-85 daysGadicke AnsbertDirector, 10% OwnerSSale−6.72K$29.20−$196.4K−2.6%250.1K after3 lots
Sep 8, 2021 (view filing)Sep 3-85 daysGadicke AnsbertDirector, 10% OwnerSSale−48.6K$29.20−$1.42M−0.6%7.69M after3 lots
Sep 8, 2021 (view filing)6:20 PM ETSep 3-85 daysMPM BioImpact LLC and 2 others10% OwnerSSale−48.6K$29.20−$1.42M−0.6%7.69M after3 lotsDuplicate filing
Sep 9, 2021 (view filing)Sep 81 dayBaeuerle PatrickSee RemarksSSale−11.0K$28.45−$312.9K−100.0%0 after
Sep 9, 2021 (view filing)Sep 81 dayTrigilio JeffreyChief Financial OfficerSSale−15.0K$28.48−$427.2K−87.0%2.25K after2 lots
Sep 13, 2021 (view filing)Sep 9-134 daysGadicke AnsbertDirector, 10% OwnerSSale−3.21K$29.23−$94.0K−1.3%246.9K after3 lots
Sep 13, 2021 (view filing)Sep 9-134 daysGadicke AnsbertDirector, 10% OwnerSSale−23.3K$29.23−$679.7K−0.3%7.66M after3 lots
Sep 13, 2021 (view filing)6:24 PM ETSep 9-134 daysMPM BioImpact LLC and 2 others10% OwnerSSale−23.3K$29.23−$679.7K−0.3%7.66M after3 lotsDuplicate filing
Sep 16, 2021 (view filing)Sep 14-152 daysGadicke AnsbertDirector, 10% OwnerSSale−1.87K$29.17−$54.5K−0.8%245.0K after2 lots
Sep 16, 2021 (view filing)Sep 14-152 daysGadicke AnsbertDirector, 10% OwnerSSale−13.5K$29.17−$394.6K−0.2%7.65M after2 lots
Sep 16, 2021 (view filing)4:45 PM ETSep 14-152 daysMPM BioImpact LLC and 2 others10% OwnerSSale−13.5K$29.17−$394.6K−0.2%7.65M after2 lotsDuplicate filing
Sep 20, 2021 (view filing)Sep 164 daysGadicke AnsbertDirector, 10% OwnerSSale−432$29.06−$12.6K−0.2%244.6K after
Sep 20, 2021 (view filing)Sep 164 daysGadicke AnsbertDirector, 10% OwnerSSale−3.12K$29.06−$90.8K0.0%7.65M after
Sep 20, 2021 (view filing)5:31 PM ETSep 164 daysMPM BioImpact LLC and 2 others10% OwnerSSale−3.12K$29.06−$90.8K0.0%7.65M afterDuplicate filing
Sep 21, 2021 (view filing)Sep 201 dayZawel LeighSee RemarksSSale−7.47K$25.16−$187.9K−11.4%57.9K after
Sep 21, 2021 (view filing)Sep 201 dayMichaelson JenniferSee RemarksSSale−4.00K$24.51−$98.0K−14.9%22.9K after2 lots
Oct 12, 2021 (view filing)Oct 75 daysZawel LeighSee RemarksSSale−1.08K$25.00−$27.0K−1.9%56.9K after
Oct 18, 2021 (view filing)Oct 153 daysZawel LeighSee RemarksSSale−19.6K$25.00−$489.4K−34.4%37.3K after
Oct 18, 2021 (view filing)Oct 153 daysTrigilio JeffreyChief Financial OfficerSSale−8.00K$25.00−$200.0K−78.0%2.25K after
Oct 20, 2021 (view filing)Oct 182 daysMichaelson JenniferSee RemarksSSale−4.00K$21.42−$85.7K−14.9%22.9K after3 lots
Apr 5, 2022 (view filing)6:45 PM ETApr 14 daysBiotechnology Value Fund L P and 9 othersOther: See Explanation of ResponsesPPurchase+276.0K$10.75+$2.97M+14.4%2.20M after2 lots
May 16, 2022 (view filing)7:34 PM ETMay 12-134 daysBiotechnology Value Fund L P and 9 othersOther: See Explanation of ResponsesPPurchase+1.11M$9.07+$10.1MNew position319.4K after5 lots
May 16, 2022 (view filing)8:54 PM ETMay 12-164 daysJovan-Embiricos Morana and 1 other10% OwnerSSale−418.7K$9.66−$4.05M−24.3%1.31M after4 lots
Jun 3, 2022 (view filing)6:24 PM ETJun 12 daysBiotechnology Value Fund L P and 9 othersOther: See Explanation of ResponsesPPurchase+751.4K$11.00+$8.26MNew position364.2K after3 lots
Jun 7, 2022 (view filing)Jun 61 dayAhmed NadimPresident and CEOPPurchase+8.09K$12.40+$100.3KNew position8.09K after
Jun 23, 2022 (view filing)6:47 PM ETJun 21-232 daysJovan-Embiricos Morana and 1 other10% OwnerSSale−101.9K$12.80−$1.30M−15.9%537.4K after3 lots
Jul 12, 2022 (view filing)Jul 111 daySavill CorrineActing Chief Business OfficerSSale−40.0K$13.33−$533.3K−19.1%169.6K after2 lots
Jul 21, 2022 (view filing)Jul 18-193 daysLateSavill CorrineActing Chief Business OfficerSSale−20.0K$15.18−$303.6K−11.8%149.6K after2 lots
Jul 26, 2022 (view filing)Jul 251 dayMichaelson JenniferChief Development OfficerSSale−8.00K$14.51−$116.1K−13.1%53.0K after
Aug 4, 2022 (view filing)9:01 PM ETAug 2-42 daysJovan-Embiricos Morana and 1 other10% OwnerSSale−49.9K$14.26−$711.7K−3.8%1.26M after3 lots
Aug 9, 2022 (view filing)Aug 81 dayMichaelson JenniferChief Development OfficerSSale−1.39K$15.01−$20.8K−2.5%53.0K after
Sep 29, 2022 (view filing)Sep 272 daysMichaelson JenniferSee RemarksSSale−4.00K$12.40−$49.6K−7.0%53.0K after
Nov 29, 2022 (view filing)Nov 254 daysMichaelson JenniferSee RemarksSSale−4.00K$13.30−$53.2K−7.0%53.0K after